Screener
Axsome Therapeutics AXSM Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
FAQ
- What is Axsome Therapeutics's free cash flow margin?
- Axsome Therapeutics (AXSM) reported free cash flow margin of -10.2% in Q1 2026.
- How has Axsome Therapeutics's free cash flow margin changed year-over-year?
- Axsome Therapeutics's free cash flow margin increased by 63.0% year-over-year, from -27.5% to -10.2%.
- What is the long-term trend for Axsome Therapeutics's free cash flow margin?
- Over 3 years (2022 to 2025), Axsome Therapeutics's free cash flow margin has grown at a -60.1% compound annual growth rate (CAGR), from -234.3% to -14.9%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.
Ask your AI about Axsome Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude